PTC Therapeutics, Inc.
PTCT
$71.70
-$0.27-0.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 32.28% | 65.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 32.28% | 65.51% | |||
| Cost of Revenue | -8.20% | -7.41% | |||
| Gross Profit | 69.02% | 480.71% | |||
| SG&A Expenses | -6.44% | -11.04% | |||
| Depreciation & Amortization | 2.25% | 23.87% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.00% | -7.65% | |||
| Operating Income | 230.43% | 155.24% | |||
| Income Before Tax | 4,062.02% | 98.23% | |||
| Income Tax Expenses | 3,948.70% | 108.43% | |||
| Earnings from Continuing Operations | 3,072.45% | 97.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3,072.45% | 97.92% | |||
| EBIT | 230.43% | 155.24% | |||
| EBITDA | 172.49% | 188.03% | |||
| EPS Basic | 3,058.53% | 97.97% | |||
| Normalized Basic EPS | 2,925.28% | 97.69% | |||
| EPS Diluted | 2,799.41% | 97.97% | |||
| Normalized Diluted EPS | 2,648.33% | 97.69% | |||
| Average Basic Shares Outstanding | 0.59% | 2.27% | |||
| Average Diluted Shares Outstanding | 11.51% | 2.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||